The clinical value of pharmacogenomics in the pharmacotherapy of common psychiatric disorders: a macroscopic analysis based on real-world data
Fei Jia·Wang, Gang, 1958 Nov. 28-·Shanshan Tian·Nan Wang·Xiaoqian Lan·Mengxi Niu·Shuang Bao·Yannan Zang·Linghui Meng·Pengfei Li·Yanjie Zhao
Abstract Background Pharmacogenomic (PGx) testing holds promise for personalized psychiatry, but its clinical utility in real-world inpatient settings remains inadequately established. Using real-world data, this study investigated whether PGx testing is associated with improved treatment outcomes in hospitalized patients with schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BD). Methods A retrospective cohort study was conducted, enrolling inpatients with SCZ, MDD, an